Contract developer Particle Sciences has nailed down a deal with Actavis, lending its drug delivery expertise to the generics giant.
Indian drugmaker Aurobindo has completed its $41 million acquisition of 7 Actavis active pharmaceutical ingredient facilities across Western Europe.
Actavis has bagged its latest catch. Fresh off last month's deal to buy Forest Laboratories in a $25 billion deal, the generics maker forked over a much smaller amount--$100 million--to buy a small generics company in Thailand.
One of Pfizer's top-selling products is suddenly vulnerable to generic competition 18 months earlier than expected. A U.S. court nixed a key Celebrex patent, putting the pain drug up for a sales fight in May. And generics makers Mylan and Actavis are promising to launch their versions as soon as Pfizer's monopoly expires.
Actavis CEO Paul Bisaro has been on a roll lately. He's scored one M&A deal after another, with Warner Chilcott wrapping up last year and Forest Laboratories currently on deck. And his pocketbook has shared in the bounty.
As Bloomberg reports, at least one analyst thinks that Valeant Pharmaceuticals, always ambitious and eager for a deal, might step in with a competing bid. Valeant is aiming to grow its way into Big Pharma, and a deal this size could really help.
After two proxy battles with Forest Labs and a settlement that warded off a third, longtime rebel investor Carl Icahn finally got his way Tuesday when Actavis announced its $25 billion buyout of the New York City-based company.
Actavis is extending its deal spree with another big buyout. The generics maker has agreed to buy Forest Laboratories for about $25 billion, in a bid to further build up its presence in branded drugs.
Generic drug maker Actavis is unloading some of its manufacturing assets as it digests the big chunk of business it bit off with its Warner Chilcott merger last year. It has reached a deal to unload its piece of a manufacturing plant in China after last week deciding to sell 7 money-losing API plants in Europe.
With a quick one-two, Actavis has bailed out of its China ventures. Just 10 days after its CEO promised to move out of a market he deemed "too risky," the Dublin-based generics maker has sold off its second business there.